新冠病毒检测与药物研发 |
|
|
|
|
抗新型冠状病毒单克隆中和抗体药物研发进展* |
史瑞,严景华() |
中国科学院微生物研究所 北京 100101 |
|
Research Progress of Neutralizing Antibody Drugs against SARS-CoV-2 |
SHI Rui,YAN Jing-hua() |
Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101,China |
[1] |
Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol, 2021, 19(3):141-154.
doi: 10.1038/s41579-020-00459-7
|
[2] |
Wiersinga W J, Rhodes A, Cheng A C, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA, 2020, 324(8):782.
doi: 10.1001/jama.2020.12839
pmid: 32648899
|
[3] |
Samrat S K, Tharappel A M, Li Z, et al. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research, 2020, 288:198141.
doi: 10.1016/j.virusres.2020.198141
|
[4] |
Wang Q H, Zhang Y F, Wu L L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, 2020, 181(4): 894-904.e9.
doi: 10.1016/j.cell.2020.03.045
|
[5] |
Costa L B, Perez L G, Palmeira V A, et al. Insights on SARS-CoV-2 molecular interactions with the renin-angiotensin system. Frontiers in Cell and Developmental Biology, 2020, 8:559841. DOI: 10.3389/fcell.2020.559841.
doi: 10.3389/fcell.2020.559841
|
[6] |
Ehrhardt S A, Zehner M, Krähling V, et al. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nature Medicine, 2019, 25(10):1589-1600.
doi: 10.1038/s41591-019-0602-4
|
[7] |
Domachowske J B, Khan A A, Esser M T, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatric Infectious Disease Journal, 2018, 37(9):886-892.
doi: 10.1097/INF.0000000000001916
|
[8] |
Gaudinski M R, Coates E E, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody MAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. The Lancet, 2019, 393(10174):889-898.
doi: 10.1016/S0140-6736(19)30036-4
|
[9] |
Shi R, Shan C, Duan X M, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020, 584(7819):120-124.
doi: 10.1038/s41586-020-2381-y
|
[10] |
Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ b cells. Cell, 2020, 182(1):73-84.
doi: 10.1016/j.cell.2020.05.025
|
[11] |
Ju B, Zhang Q, Ge J W, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584(7819):115-119.
doi: 10.1038/s41586-020-2380-z
|
[12] |
Chi X Y, Yan R H, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science, 2020, 369(6504):650-655.
doi: 10.1126/science.abc6952
|
[13] |
Wang Q, Yang H, Liu X, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science Translational Medicine, 2016, 8(369): 369ra179.
|
[14] |
King D J, Bowers P M, Kehry M R, et al. Mammalian cell display and somatic hypermutation in vitro for human antibody discovery. Curr Drug Discov Technol, 2014, 11(1):56-64.
doi: 10.2174/15701638113109990037
|
[15] |
Li Y, Wan Y H, Liu P P, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Research, 2015, 25(11):1237-1249.
doi: 10.1038/cr.2015.113
|
[16] |
Yang L F, Liu W H, Yu X, et al. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Therapeutics, 2020, 3(3):205-212.
doi: 10.1093/abt/tbaa020
|
[17] |
Jones B E, Brown-Augsburger P L, Corbett K S, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv, 2020, DOI: 10.1101/2020.09.30.318972.
|
[18] |
Gottlieb R L, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA, 2021, 325(7):632.
doi: 10.1001/jama.2021.0202
|
[19] |
Hansen J, Baum A, Pascal K E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, 2020, 369(6506):1010-1014.
doi: 10.1126/science.abd0827
|
[20] |
Weinreich D M, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. New England Journal of Medicine, 2021, 384(3):238-251.
doi: 10.1056/NEJMoa2035002
|
[21] |
Pinto D, Park Y J, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020, 583(7815):290-295.
doi: 10.1038/s41586-020-2349-y
pmid: 32422645
|
[22] |
Bournazos S, Corti D, Virgin H W, et al. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature, 2020, 588(7838):485-490.
doi: 10.1038/s41586-020-2838-z
|
[23] |
Dong J H, Zost S J, Greaney A J, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv, 2021, DOI: 10.1101/2021.01.27.428529.
|
[24] |
Cheolmin K, Dong-Kyun R, Lee J H, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun, 2021, 12(1):288.
doi: 10.1038/s41467-020-20602-5
|
[25] |
Lv Z, Deng Y Q, Ye Q, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science, 2020, 369(6510):1505-1509.
doi: 10.1126/science.abc5881
|
[26] |
Bournazos S, Gupta A, Ravetch J V. The role of IgG Fc receptors in antibody-dependent enhancement. Nature Reviews Immunology, 2020, 20(10):633-643.
doi: 10.1038/s41577-020-00410-0
|
[27] |
Lee W S, Wheatley A K, Kent S J, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology, 2020, 5(10):1185-1191.
doi: 10.1038/s41564-020-00789-5
|
[28] |
Arvin A M, Fink K, Schmid M A, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 2020, 584(7821):353-363.
doi: 10.1038/s41586-020-2538-8
pmid: 32659783
|
[29] |
Mackness B C, Jaworski J A, Boudanova E, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. mAbs, 2019, 11(7):1276-1288.
doi: 10.1080/19420862.2019.1633883
pmid: 31216930
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|